LPA and atherosclerosis: In addition to PCSK9 inhibitors and Lp(a)-targeted RNA-based agents, several other pharmacologic strategies, both established and emerging, are being explored for their ability to modulate shared pathogenic pathways in atherosclerosis and CAVS.